DRI Capital to float pharma royalties fund in London

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity IPOs

DRI Capital to float pharma royalties fund in London

Aidan Gregory
February 12, 2020 09:00 am
DRI_Capital_PA_575_375
Pharmaceuticals being produced at the company STADA Azneimittel AG in Bad Vilbel, Germany, 20 June 2016. STADA specialised on the production of generic medicaments and over-the-counter pharmaceuticals for pharmacies. PHOTO: FRANK RUMPENHORST/dpa | Frank Rumpenhorst/DPA/PA Images

Canada’s DRI Capital is preparing to list a new fund on the London Stock Exchange focused on investing in pharmaceuticals royalties.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOsHealth and BiotechCanadaEquityUKAmericasEuropeNorth AmericaEMEASRIJefferies LLC
AG
Aidan Gregory
Gift this article